Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribociclib + spartalizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ribociclib + spartalizumab is an investigational combination therapy consisting of ribociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and spartalizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Ribociclib inhibits CDK4/6 to block cell cycle progression in cancer cells. Spartalizumab blocks PD-1 to enhance T-cell mediated immune responses against tumors. The combination has been studied primarily in advanced solid tumors such as hormone receptor-positive/HER2-negative metastatic breast cancer and recurrent/metastatic head and neck squamous cell carcinoma. Early-phase clinical trials have shown limited efficacy for the doublet with notable hepatotoxicity when combined with endocrine therapy[1][5]. Development was discontinued for some indications due to safety concerns.
- Brand names
- Kisqali (ribociclib)
- Other names
- spartalizumab + ribociclib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on ribociclib + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribociclib + spartalizumab.